Literature DB >> 8582543

A preponderance of small dense LDL is associated with specific insulin, proinsulin and the components of the insulin resistance syndrome in non-diabetic subjects.

S M Haffner1, L Mykkänen, D Robbins, R Valdez, H Miettinen, B V Howard, M P Stern, R Bowsher.   

Abstract

Recently, the presence of small dense low density lipoprotein (LDL) has been postulated to be a stronger risk factor for coronary heart disease than large LDL. While small dense LDL has been associated with individual components of the insulin resistance syndrome such as hypertension, high triglyceride level, low high density (HDL) cholesterol, and diabetes mellitus, there has been little work exploring whether LDL size is decreased in subjects with multiple metabolic disorders. We examined the association of LDL size and pattern to specific insulin (which does not cross-react with proinsulin), proinsulin, increased triglyceride, decreased HDL, hypertension and impaired glucose tolerance in 488 non-diabetic subjects from the San Antonio Heart Study. LDL size was significantly related to specific insulin, proinsulin and the fasting proinsulin/insulin ratio. Small dense LDL was significantly associated with high triglyceride level, decreased HDL cholesterol, hypertension and impaired glucose tolerance. LDL size (A) decreased in a stepwise fashion with increasing number of the metabolic disorders described above (zero 262.6 +/- 9.4; one 257.0 +/- 9.3; two 256.4 +/- 9.4; three 249.0 +/- 9.1; and four 244.9 +/- 9.0). These results were similar in men and women and in non-Hispanic whites and Mexican Americans. The association between LDL size and the number of metabolic disorders remained statistically significant even after adjustment for obesity, body fat distribution, gender, ethnicity, proinsulin and insulin concentrations. Furthermore, decreases in LDL size are also significantly associated with both a selective beta-cell defect (as estimated by the fasting proinsulin/insulin ratio) and insulin resistance (as estimated by the fasting insulin concentrations) although the association was somewhat stronger for the latter. We conclude that small dense LDL may form part of the insulin resistance syndrome in non-diabetic subjects.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8582543     DOI: 10.1007/bf00401766

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  47 in total

1.  The hypertension detection and follow-up program: Hypertension detection and follow-up program cooperative group.

Authors: 
Journal:  Prev Med       Date:  1976-06       Impact factor: 4.018

2.  Prospective analysis of the insulin-resistance syndrome (syndrome X).

Authors:  S M Haffner; R A Valdez; H P Hazuda; B D Mitchell; P A Morales; M P Stern
Journal:  Diabetes       Date:  1992-06       Impact factor: 9.461

3.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

Authors: 
Journal:  JAMA       Date:  1993-06-16       Impact factor: 56.272

4.  Influence of obesity, impaired glucose tolerance, and NIDDM on LDL structure and composition. Possible link between hyperinsulinemia and atherosclerosis.

Authors:  H A Barakat; J W Carpenter; V D McLendon; P Khazanie; N Leggett; J Heath; R Marks
Journal:  Diabetes       Date:  1990-12       Impact factor: 9.461

5.  Hyperinsulinemia in a population at high risk for non-insulin-dependent diabetes mellitus.

Authors:  S M Haffner; M P Stern; H P Hazuda; J A Pugh; J K Patterson
Journal:  N Engl J Med       Date:  1986-07-24       Impact factor: 91.245

6.  Low-density lipoprotein subclass patterns and risk of myocardial infarction.

Authors:  M A Austin; J L Breslow; C H Hennekens; J E Buring; W C Willett; R M Krauss
Journal:  JAMA       Date:  1988-10-07       Impact factor: 56.272

7.  Apolipoprotein, low density lipoprotein subfraction, and insulin associations with familial combined hyperlipidemia. Study of Utah patients with familial dyslipidemic hypertension.

Authors:  S C Hunt; L L Wu; P N Hopkins; B M Stults; H Kuida; M E Ramirez; J M Lalouel; R R Williams
Journal:  Arteriosclerosis       Date:  1989 May-Jun

8.  Plasma insulin and lipoprotein concentrations: an atherogenic association?

Authors:  T J Orchard; D J Becker; M Bates; L H Kuller; A L Drash
Journal:  Am J Epidemiol       Date:  1983-09       Impact factor: 4.897

9.  Insulin deficiency and increased plasma concentration of intact and 32/33 split proinsulin in subjects with impaired glucose tolerance.

Authors:  M J Davies; G Rayman; I P Gray; J L Day; C N Hales
Journal:  Diabet Med       Date:  1993-05       Impact factor: 4.359

10.  Insulin deficiency rather than hyperinsulinaemia in newly diagnosed type 2 diabetes mellitus.

Authors:  M J Davies; J Metcalfe; I P Gray; J L Day; C N Hales
Journal:  Diabet Med       Date:  1993-05       Impact factor: 4.359

View more
  8 in total

1.  Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population.

Authors:  B Fagerberg; S Edwards; T Halmos; J Lopatynski; H Schuster; S Stender; G Stoa-Birketvedt; S Tonstad; S Halldórsdóttir; I Gause-Nilsson
Journal:  Diabetologia       Date:  2005-07-07       Impact factor: 10.122

Review 2.  Diabetic dyslipidaemia: current treatment recommendations.

Authors:  J D Best; D N O'Neal
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

3.  Serum small dense low-density lipoprotein concentrations are elevated in patients with significant coronary artery stenosis and are related to features of the metabolic syndrome.

Authors:  Shima Yazdandoust; Seyyed Mohammad Reza Parizadeh; Mohsen Moohebati; Parichehreh Yaghmaei; Amir Ali Rahsepar; Shima Tavallaie; Mohammad Soukhtanloo; Roshanak Khojasteh; Roghayeh Paydar; Afsoon Fazlinezhad; Homa Falsoleiman; Mashalla Dehghani; Majid Ghayour-Mobarhan; Gordon A Ferns
Journal:  Lipids       Date:  2012-08-18       Impact factor: 1.880

4.  Low-density lipoprotein particle size in hepatic steatosis and metabolic syndrome.

Authors:  Dal-Sik Kim; Young-Kon Kim; Do-Sung Kim; Han-Jung Chae; Tae-Sun Park; Young I Cho; Seul-Ki Jeong
Journal:  Diabetol Metab Syndr       Date:  2010-03-22       Impact factor: 3.320

5.  Prepregnancy Adverse Lipid Profile and Subsequent Risk of Gestational Diabetes.

Authors:  Emily S Han; Ronald M Krauss; Fei Xu; Sneha B Sridhar; Assiamira Ferrara; Charles P Quesenberry; Monique M Hedderson
Journal:  J Clin Endocrinol Metab       Date:  2016-04-05       Impact factor: 5.958

6.  Plasma lipoprotein-associated phospholipase A2 in patients with metabolic syndrome and carotid atherosclerosis.

Authors:  Hui-Ping Gong; Yi-Meng Du; Li-Na Zhong; Zhao-Qiang Dong; Xin Wang; Yong-Jun Mao; Qing-Hua Lu
Journal:  Lipids Health Dis       Date:  2011-01-19       Impact factor: 3.876

7.  Small Dense LDL Tied to Diabetic Retinopathy-Similarity to Atherosclerosis.

Authors:  Tsutomu Hirano
Journal:  J Atheroscler Thromb       Date:  2021-05-28       Impact factor: 4.394

Review 8.  The prothrombotic tendency in metabolic syndrome: focus on the potential mechanisms involved in impaired haemostasis and fibrinolytic balance.

Authors:  Isabella Russo
Journal:  Scientifica (Cairo)       Date:  2012-08-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.